Navigation Links
Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
Date:4/25/2008

Ohm Laboratories to Market in OTC Private Label Market

PRINCETON, N.J., April 25 /PRNewswire/ -- Ohm Laboratories Inc (Ohm), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1 mg/mL (OTC). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ohm formulation to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Children's Zyrtec Oral Solution (Allergy) and Children's Zyrtec Oral Solution (Hives-Relief), 1mg/mL of McNeil Consumer Healthcare. Total annual market sales for Cetirizine Hydrochloride Syrup as a prescription only product were $157 million (IMS - MAT: December 2007).

Cetirizine Hydrochloride is indicated for the temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, watery eyes due to hay fever or other upper respiratory allergies. Other indications include relief from itching due to hives (urticaria).

"We are pleased to receive this final approval for Cetirizine Hydrochloride Oral Solution that has proven its clinical value and utility in both adults and children. We are pleased to offer this preferred formulation that will meet the needs of all patients who need this medication in response to allergic reactions as an over-the-counter product. This product formulation further expands our portfolio of affordable generic alternatives and will be launched immediately to all classes of trade participating in the OTC private label market," said Jim Meehan, Vice President of Sales and Distribution for Ohm Laboratories, a wholly owned subsidiary company of RLL.

Ohm, based in North Brunswick, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Ind
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
2. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
3. Ranbaxy Receives Tentative Approval For Valsartan Tablets
4. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
5. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Michael E. DeBakey Receives Congressional Gold Medal
8. Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum
9. Cadient Group Receives Multiple Awards at 2008 DTC National Advertising Awards
10. The National Exercise & Sports Trainers Association Receives Accreditation of Its Personal Fitness Trainer Certification From the National Commission for Certifying Agencies (NCCA)
11. PainCare Receives Notices From American Stock Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... seeking better therapeutic options to efficiently cure and prevent different malignancies. Some ... cancers have different pathophysiological properties due to which distinctive approach is necessary ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound ... a wound to remove exudates, fluid, and infectious materials to prepare the wound ... devices, disposable devices, and canisters, etc.) is projected to expand continuously through 2021. ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Information Management has been granted continued accreditation based on a successfully completed ... ÔÇťAchieving and maintaining this accreditation takes the involvement and dedication of each ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... government entities, announced today that it has hired Scott Sanderson, an experienced business ... this capacity, Sanderson will be responsible for establishing and managing new client relationships ...
(Date:9/1/2015)... ... 2015 , ... WorkCare, Inc., a national occupational health services ... as an Associate Medical Director. , WorkCare specializes in workforce health protection ... abroad. , Dr. Nelson has a diverse background. He trained in sports ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... Seeking Feedback on Revisions to Standards , , WASHINGTON, ... comprehensive review of its standards, URAC , ... for public comment on revisions to its Health ... Security standards . URAC welcomes purchasers, policy ...
... June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals Enterprises, Inc. (OTC ... company with its principal operations in the,People,s Republic ... the China New,Drugs Trade Fair from June 26 ... Exhibition Center, and also plans to launch a ...
... , DENVER, June 18 DaVita Inc. (NYSE: ... those diagnosed with chronic kidney disease (CKD), today announced the ... Work for in Colorado Program. DaVita(R) is the only ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) , , "We ...
... ... Southeast Asia,s largest private hospital and one of the world,s top medical travel destinations, ... Quality Class (TQC) award for 2008. , ... Bangkok, Thailand (PRWEB) June 18, 2009 -- Bumrungrad International ...
... ... has been validated by ACHC as an organization dedicated to quality patient services, and ... ... -- Homefront Diabetic Services proudly announces its award of accreditation status by the Accreditation ...
... approach to choosing the best treatment options for early breast ... in a report from the 11th St Gallen conference. ... Annals of Oncology [1] today (Thursday 18 June), and ... from the conference of more than 4,800 participants from 101 ...
Cached Medicine News:Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 2Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 3Health News:Public Comment Period Open for HIPAA Privacy and Security Standards 4Health News:Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 2Health News:Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 3Health News:DaVita Named One of Best Companies to Work for in Colorado 2Health News:Bumrungrad International the first private hospital to be awarded Thailand Quality Class (TQC) for organizational excellence 2Health News:Bumrungrad International the first private hospital to be awarded Thailand Quality Class (TQC) for organizational excellence 3Health News:Homefront Diabetic Services Completes Accreditation with ACHC 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 2Health News:St. Gallen consensus 2009: A radically different approach to treating early breast cancer 3
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Conn. , Sept. 1, 2015  Results from ... AD™ study demonstrate that 5g of idarucizumab enabled ... situations involving patients treated with dabigatran (Pradaxa ® ... of the anticoagulant effect of dabigatran enabled patients ... a median time of 1.7 hours between administration ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... N.Y., Aug. 17, 2011 Polymedco is pleased ... Colorectal Cancer Screening in Integrated Health Care Systems" ... Burley, Juan Reyes, Michael Oehrli, and Cindy Caldwell ... screening program for Colorectal cancer (CRC) at Kaiser ...
... 17, 2011  ConvaTec, a world-leading developer and marketer ... today announced the appointments of Charles Cerminara and James ... has been appointed Vice President and General Manager, Greater ... on the growth of the Chinese market and to ...
Cached Medicine Technology:Polymedco Announces Publication in Epidemiologic Reviews 2ConvaTec Announces Asia-Pacific Leadership Appointments 2
CataRhex PRO the portable cataract extraction system with automated capsulotomy....
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
Aaron Burr II with disposable 1mm burr for corneal rust ring removal and a diamond burr tip for polishing the pterygium bed after surgical removal and for lid margin lesions....
Algerbrush II corneal rust ring remover battery powered...
Medicine Products: